MIRA Pharmaceuticals, Inc. (MIRA)

Import this data to Google Sheets with:

=jivedata("MIRA","financials")

Full statements spill as a table. For one cell: =jivedata("MIRA","Revenue") or =jivedata("MIRA","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

MIRA Pharmaceuticals, Inc.

MIRA • CIK 0001904286

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-11,982.343	$-7,852.659	$-10,442.485	$-9,479.68
Preferred Stock Dividends, Income Statement Impact	—	—	$21,556.821	$21,556.821
Net Income (Loss) Available to Common Stockholders, Basic	—	—	$-31,999.306	$-31,999.306
Weighted Average Number of Shares Outstanding, Basic	18,566,158	15,444,149	23,694,333	48,316,013
General and Administrative Expense	$6,499.537	$4,712.753	$8,773.329	$7,261.658
Research and Development Expense	$1,572.962	$3,305.575	$1,719.783	$2,139.752
Operating Expenses	$8,526.049	$8,018.328	$10,493.112	$9,401.41
Interest Income (Expense), Net	—	—	$98.911	$149.14
Other Nonoperating Expense	—	—	$13.072	$13.072
Unrealized Gain (Loss) on Investments	—	—	$-35.212	$-35.212
Other Nonoperating Income (Expense)	—	—	$50.627	$-48.226

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Liabilities	$558.097	$723.349	$702.068	$40.823
Liabilities and Equity	$4,932.443	$2,923.099	$11,093.605	$8,203.14
Cash and Cash Equivalents, at Carrying Value	—	—	$6,346.921	$3,609.442
Prepaid Expense, Current	$243.802	$54.729	$28.146	$54.286
Short-term Investments	—	—	$4,683.099	$4,503.973
Assets, Current	$4,858.23	$2,887.66	$11,058.166	$8,167.701
Other Receivables	$69.152	—	—	$69.152
Accounts Payable, Current	—	—	$129.203	$40.823
Other Liabilities, Current	—	—	$572.865	$572.865
Common Stock, Value, Issued	$1.478	$1.656	$4.194	$4.202
Additional Paid in Capital	$25,657.93	$31,335.815	$49,967.549	$50,097.007
Retained Earnings (Accumulated Deficit)	$-21,285.062	$-29,137.721	$-39,580.206	$-41,938.892
Stockholders' Equity Attributable to Parent	$4,374.346	$2,199.75	$10,391.537	$8,162.317
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	100,000,000	100,000,000	100,000,000	100,000,000
Common Stock, Shares, Issued	14,780,885	16,560,852	41,938,587	42,022,087

(in thousands, except per share data)	FY 2023	FY 2024	FY 2025	TTM
Net Income (Loss) Attributable to Parent	$-11,982.343	$-7,852.659	$-10,442.485	$-9,479.68
Net Cash Provided by (Used in) Financing Activities	$8,783.991	$3,790.971	$8,175.659	$7,517.83
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$4,251.588	$-1,769.635	$3,513.99	$2,878.967
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$4,602.566	$2,832.931	$6,346.921	$9,955.667
Share-based Payment Arrangement, Noncash Expense	$2,550.946	$1,920.805	$6,313.167	$5,078.255
Unrealized Gain (Loss) on Investments	—	—	$-35.212	$-35.212
Proceeds from (Repayments of) Notes Payable	—	—	$572.865	$572.865
Proceeds from Stock Options Exercised	—	—	$888.282	$888.282
Proceeds from Contributions from Affiliates	—	—	$33.713	$33.713
Proceeds from Issuance of Common Stock	$7,704.279	$3,608.555	$7,006.982	$7,006.982
Increase (Decrease) in Prepaid Expense	$243.802	$-189.073	$-26.583	$-48.117
Increase (Decrease) in Other Receivables	—	$-11.862	$-11.862	$-11.862
Increase (Decrease) in Accounts Payable and Accrued Liabilities	$-389.524	$184.785	$-594.146	$-257.635
Increase (Decrease) in Accrued Interest Receivable, Net	—	—	$14.472	—
Net Cash Provided by (Used in) Operating Activities	$-4,532.403	$-5,560.606	$-4,661.669	$-4,638.863

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("MIRA","financials")

Full statements spill as a table. For one cell: =jivedata("MIRA","Revenue") or =jivedata("MIRA","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.